Publicis Groupe Half-Year Financial Statement Liquidity Contract

PARIS, July 3, 2015 (GLOBE NEWSWIRE) -- Under the liquidity contract of Publicis Groupe [Euronext Paris: FR0000130577, CAC40] with Kepler Capital Markets SA, the following means were attributable to the liquidity contract at June 30, 2015:

- 270,000 Publicis Groupe shares - €4,773,294

It is reminded that at December 31, 2014, the following means appeared in the contract:

- 22,830 Publicis Groupe shares - €15,309,624.39

About Publicis Groupe Publicis Groupe [Euronext Paris FR0000130577, CAC 40] is a global leader in marketing, communication, and business transformation. In a world marked by increased convergence and consumer empowerment, Publicis Groupe offers a full range of services and skills: digital, technology & consulting with Publicis.Sapient (SapientNitro, Sapient Global Markets, Sapient Government Services, Razorfish Global, DigitasLBi, Rosetta) - the world's largest most forward-thinking digitally centered platform focused exclusively on digital transformation in an always-on world - as well as creative networks such as BBH, Leo Burnett, Publicis Worldwide, Saatchi & Saatchi, public affairs, corporate communications and events with MSLGROUP, ad tech solutions with VivaKi, media strategy, planning and buying through Starcom MediaVest Group and ZenithOptimedia, healthcare communications, with Publicis Healthcare Communications Group (PHCG), and finally, brand asset production with Prodigious. Present in 108 countries, the Groupe employs more than 76,000 professionals.

www.publicisgroupe.com | Twitter: @PublicisGroupe | Facebook: www.facebook.com/publicisgroupe | LinkedIn: Publicis Groupe | http://www.youtube.com/user/PublicisGroupe | Viva la Difference ! Contacts

HUG#1934184

You May Also Be Interested In

• Beazer Homes closes $400M senior notes offering due 2032
• First Atlantic Nickel & Cobalt Produces High Grade Alloy Concentrate Up to 71.9% Nickel and 1.76% Cobalt from Its Pipestone XL Nickel-Cobalt Alloy Project, Using Its First-Ever ONSHORE MAX (Magnet
• FDA backs Entera Bio's Phase 3 trial plan for oral osteoporosis drug